|
|
| | Etodesnitazene (citrate) Basic information |
| | Etodesnitazene (citrate) Chemical Properties |
| solubility | DMF: 10 mg/ml
DMSO: 10 mg/mlPBS (pH 7.2): 1 mg/ml |
| | Etodesnitazene (citrate) Usage And Synthesis |
| Description | Etodesnitazene (citrate) (Item No. 29916) is an analytical reference standard categorized as an opioid.1 Etodesnitazene is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications. WARNING This product is not for human or veterinary use. | | References | [1] MARTHE M. VANDEPUTTE. Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids.[J]. ACS Chemical Neuroscience, 2021. DOI: 10.22541/au.160520665.59016513/v2
[2] KYOKO HATAOKA. Evaluation of rewarding effects of nitazene analogs: results from conditioned place preference tests and in vivo microdialysis experiments in mice.[J]. Journal of Toxicological Sciences, 2025, 50 1: 33-43. DOI: 10.2131/jts.50.33
[3] LAURA B KOZELL. Pharmacologic Characterization of Substituted Nitazenes at μ, κ, and Δ Opioid Receptors Suggests High Potential for Toxicity.[J]. Journal of Pharmacology and Experimental Therapeutics, 2024: 219-228. DOI: 10.1124/jpet.123.002052
[4] OMAYEMA TAOUSSI. Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene[J]. Archives of Toxicology, 2024, 98 7: 2101-2116. DOI: 10.1007/s00204-024-03735-0 |
| | Etodesnitazene (citrate) Preparation Products And Raw materials |
|